Publications & News

WilmerHale Counsels Voyager Therapeutics in Global Strategic Collaboration with AbbVie

March 14, 2018

Voyager Therapeutics, Inc., a clinical-stage gene therapy company, and AbbVie, a global biopharmaceutical company, announced that they have entered into an exclusive strategic collaboration and option agreement to develop and commercialize vectorized antibodies directed against tau for the treatment of Alzheimer's disease and other neurodegenerative diseases. Voyager Therapeutics will receive a $69 million upfront payment and potentially up to $155 million in preclinical and Phase 1 option payments as well as development and regulatory milestone payments and royalties.

The WilmerHale team counseling Voyager Therapeutics included Belinda Juran, Steve Singer, Lily Wound and Elizabeth Mayo.

Read the press release for more information.